English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Esophageal cancer is the fourth most frequently diagnosed cancer in China (1). Esophageal squamous cell carcinoma (ESCC) represents over 90 percent of esophageal carcinoma in high-risk regions (2). Although there has been considerable progress in the development of treatments and therapeutic interventions, including chemotherapy, radiation, and surgery, the prognosis for ESCC patients is still poor due to the high incidence of local and metastatic recurrence (3). ESCC patients generally have a 5-year overall survival (OS) rate of below 28% (4) and the clinical variables commonly used for outcome prediction are not Original Article

Preoperative lymphocyte-monocyte ratio is not an independent prognostic factor in M0 (stage I–III) esophageal squamous cell carcinomas